Clinical trialNCT05029999RecruitingPhase 1Interventional

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

SponsorUniversity of Texas Southwestern Medical CenterEnrollment30HER2-negative Breast CancerMetastatic Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer, and to determine a safe dose and treatment schedule of the three drugs. This research study will also test how your immune system responds to these treatments alone and in combination.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Sangeetha Reddy
University of Texas Southwestern Medical Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Recruiting
Johns Hopkins University
Baltimore, Maryland, United States
Recruiting
University of North Carolina
Chapel Hill, North Carolina, United States
Yara G Abdou, MD
Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Withdrawn
Texas Oncology, P.A.
Dallas, Texas, United States
Active, not recruiting
Ut Southwestern Medical Center
Dallas, Texas, United States
Recruiting
the University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CDX-1140CDX-301PLD Chemotherapy

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 20 Apr 2022
Primary completion: 20 Apr 2028
Completion: 20 Apr 2029
Last update posted: 17 Jun 2026
Registered enrollment: 30
Registry id: NCT05029999

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.